|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03320 CHINARES PHARMA
Nominal 
4.650 0.000 (0.000%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 HKD(K$) | |
| Turnover | 134,457,581 | 1.965% | 131,866,817 | 128,597,588 | 122,818,429 | 125,716,477 |
| Cost of Sales | (112,923,458) | 2.325% | (110,357,203) | (107,664,092) | (103,057,803) | (105,884,796) |
| Gross Profit | 21,534,123 | 0.114% | 21,509,614 | 20,933,496 | 19,760,626 | 19,831,681 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 134,088 | 18.415% | 113,236 | 198,770 | 212,013 | 185,914 | |
| Profit / (Loss) before Taxation | 6,444,776 | 0.449% | 6,415,965 | 7,046,076 | 6,283,235 | 6,581,117 | |
| Taxation | (1,421,271) | 4.327% | (1,362,328) | (1,505,520) | (1,254,086) | (1,412,765) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (2,836,873) | -4.686% | (2,976,355) | (2,935,750) | (2,347,480) | (2,143,306) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,186,632 | 5.264% | 2,077,282 | 2,604,806 | 2,681,669 | 3,025,046 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 HKD(K$) | |
| Net Finance Costs / (Income) | 708,602 | -3.592% | 735,003 | 805,838 | 1,196,310 | 932,461 |
| Depreciation & Amortisation | 2,122,917 | 12.469% | 1,887,553 | 1,628,020 | 1,529,515 | 1,602,815 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| EPS (cts) | 35.000 | 6.061% | 33.000 | 41.000 | 43.000 | 48.000 |
| DPS (cts) | 8.700 | -- | 7.200 | 8.300 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | 24.857% | -- | 21.818% | 20.244% | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 8.404 | -- | 7.953 | 7.699 | 7.398 | 8.045 |
| Remarks: | Real time quote last updated: 26/08/2026 08:20 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,186,632 |
| %Change | 5.264% |
| EPS / (LPS) | RMB 0.350 |
| NBV Per Share (¥) | RMB 8.404 |